Vaishali Pharma (VAISHALI) Q2 25/26 earnings summary

Executive summary

• Un-audited financial results for the quarter and half year ended September 30, 2025, were approved by the Board and reviewed by statutory auditors, with no material misstatements identified.

Financial highlights

• Standalone revenue from operations for H1 FY26 was ₹5,719.34 lakhs, up from ₹3,886.55 lakhs in H1 FY25.

• Standalone net profit for H1 FY26 was ₹246.38 lakhs, compared to ₹81.74 lakhs in H1 FY25.

• Consolidated net profit for H1 FY26 was ₹246.57 lakhs, including ₹0.19 lakhs share of profit from associate.

• Earnings per share (basic and diluted) for H1 FY26 stood at ₹0.19, up from ₹0.06 in H1 FY25.

Outlook and guidance

• The company continues to focus on its core segment of pharmaceutical product sales.